Impact of Pharmaceutical Care Interventions on Clinical Outcomes in Type II Diabetes Mellitus: Current Evidence, Challenges, and Future Perspectives

Abstract

Type II Diabetes Mellitus (T2DM) is a rapidly growing global health concern associated with significant morbidity, mortality, and economic burden. Despite advances in pharmacotherapy, achieving optimal glycemic control remains a major challenge due to poor adherence, complex treatment regimens, and fragmented healthcare delivery. Pharmaceutical care, a patient- centred approach led by pharmacists, has emerged as an effective strategy to improve diabetes management outcomes. This review critically evaluates evidence from interventional studies demonstrating the impact of pharmacist-led services, including medication therapy management (MTM), patient counselling, lifestyle modification support, and continuous monitoring. These interventions have been consistently associated with significant reductions in HbA1c (0.5–2%), improved medication adherence, enhanced quality of life, and decreased hospitalisation rates. The review further explores the integration of emerging technologies such as mobile health (mHealth), telepharmacy, clinical decision support systems (CDSS), and artificial intelligence (AI) in optimising pharmaceutical care delivery. Key barriers, including healthcare system limitations, lack of reimbursement policies, and interdisciplinary coordination challenges, are also discussed.